# US 2025/0154252 A1 · Treatment of cardiovascular diseases using anti-human gpvi antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154252 A1
- Document ID: US20250154252A1
- Status: Published application
- Kind: A1
- Application number: 18/840,227
- Filed: 2023-02-21
- Published: 2025-05-15
- Earliest claimed: 2022-02-21
- Assignees: Acticor Biotech
- Applicants: Acticor Biotech
- Inventors: Gilles AVENARD; Yannick PLETAN; Jean-Marie GROUIN; Sophie BINAY; Elie TOLEDANO; Andrea COMENDUCCI
- Web page: https://patentgrep.com/patent/US20250154252A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/39533: {against materials from animals}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An inhibitor of GPVI signaling pathway, in particular an isolated humanized protein binding to human Glycoprotein VI (hGPVI), for treating a GPVI-related condition in a subject in need thereof, in particular an acute ischemic stroke, including the administration of the inhibitor GPVI signaling pathway, in particular the anti-human glycoprotein VI antibody or fragment thereof, to a human patient in need thereof.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method for treating a GPVI-related condition in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an isolated humanized protein binding to human Glycoprotein VI (hGPVI), wherein said subject presents at least one of the following conditions:
said subject is affected with a moderate to severe GPVI-related condition,
said subject is of 65 years of age or older, and/or
said subject is undergoing or has undergone thrombectomy and thrombolysis,
preferably wherein said GPVI-related condition is a stroke, more preferably an acute ischemic stroke.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the isolated humanized protein binding to hGPVI is an antibody molecule or an antibody fragment selected from the group consisting of a whole antibody, a single chain antibody, a Fv, a Fab, a unibody, a domain antibody, and a nanobody; or a monomeric antibody mimetic selected from the group consisting of an affibody, an affilin, an affitin, an adnectin, an atrimer, an evasin, a DARPin, an anticalin, an avimer, a fynomer, and a versabody, preferably the isolated humanized protein is a monovalent antibody or fragment thereof.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the isolated humanized protein binding to hGPVI is an antibody molecule or an antibody fragment,
the variable region of the heavy chain comprises at least one of the following CDRs:
VH-CDR1:
(SEQ ID NO: 1)
GYTFTSYNMH;
VH-CDR2:
(SEQ ID NO: 2)
GIYPGNGDTSYNQKFQG;
and
VH-CDR3:
(SEQ ID NO: 3)
GTVVGDWYFDV;
or any CDR having an amino acid sequence that shares at least 60% of identity with SEQ ID NO: 1-3; and
the variable region of the light chain comprises at least one of the following CDRs:
VL-CDR1:
(SEQ ID NO: 4)
RSSQSLENSNGNTYLN;
VL-CDR2:
(SEQ ID NO: 5)
RVSNRFS;
and
VL-CDR3:
(SEQ ID NO: 6)
LQLTHVPWT;
or any CDR having an amino acid sequence that shares at least 60% of identity with SEQ ID NO: 4-6.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the isolated humanized protein binding to hGPVI is an antibody molecule or an antibody fragment, the variable region of the heavy chain comprises the following CDRs: GYTFTSYNMH (SEQ ID NO: 1), GIYPGNGDTSYNQKFQG (SEQ ID NO: 2) and GTVVGDWYFDV (SEQ ID NO: 3) and the variable region of the light chain comprises the following CDRs: RSSQSLENSNGNTYLN (SEQ ID NO: 4), RVSNRFS (SEQ ID NO: 5) and LQLTHVPWT (SEQ ID NO: 6) or any CDR having an amino acid sequence that shares at least 60% of identity with said SEQ ID NO: 1-6.

### Claim 21 (depends on 17)

The method according to claim 17, wherein the isolated humanized protein binding to hGPVI is an antibody molecule or an antibody fragment, the amino acid sequence encoding the heavy chain variable region is SEQ ID NO: 7 and the amino acid sequence encoding the light variable region is SEQ ID NO: 8, or any sequence having an amino acid sequence that shares at least 60% of identity with said SEQ ID NO: 7 or 8.

### Claim 22 (depends on 17)

The method according to claim 17, wherein the isolated humanized protein binding to hGPVI is an antibody molecule or an antibody fragment, the amino acid sequence encoding the heavy chain variable region is SEQ ID NO: 7 and the amino acid sequence encoding the light variable region is SEQ ID NO: 9, or any sequence having an amino acid sequence that shares at least 60% of identity with said SEQ ID NO: 7 or 9.

### Claim 23 (depends on 17)

The method according to claim 17, wherein the GPVI-related condition is a stroke, and wherein the severity of the stroke is evaluated by the NIH stroke scale (NIHSS), preferably wherein said subject affected with a stroke has a NIHSS score at baseline equal to or greater than 10.

### Claim 24 (depends on 17)

The method according to claim 17, wherein said GPVI-related condition is an ischemic stroke, preferably an acute ischemic stroke.

### Claim 25 (depends on 17)

The method according to claim 17, wherein said subject has received, is receiving or will receive a thrombolytic agent, and/or an anticoagulant, and/or an antiplatelet agent.

### Claim 26 (depends on 17)

The method according to claim 17, wherein said subject is of 80 years of age or older.

### Claim 27 (depends on 17)

The method according to claim 17, wherein said protein prevents the occurrence of intracranial hemorrhages in the subject.

### Claim 28 (depends on 17)

The method according to claim 17, wherein said protein decreases the risk of death of the subject, preferably the risk of death within a time period of 20 days after the onset of the GPVI-related condition, more preferably 10 days after the onset of the GPVI-related condition, and even more preferably the risk of death within a time period of 5 days after the onset of the GPVI-related condition.

### Claim 29 (depends on 17)

The method according to claim 17, wherein said protein decreases the degree of disability or dependence following the GPVI-related condition.

### Claim 30

A method for decreasing the degree of disability or dependence following a GPVI-related condition, such as a stroke, in a subject, comprising administering to said subject a therapeutically effective amount of an isolated humanized protein binding to human Glycoprotein VI (hGPVI), preferably the method decreasing the risk of having a modified Rankin Scale (mRS) score measured 90 days after the administration of the isolated humanized protein equal to or greater than 4 or increasing the probability of having a mRS score measured 90 days after the administration of the isolated humanized protein equal to or lower than 3.

### Claim 31

A method for preventing the occurrence of intracranial hemorrhages in a subject affected with a GPVI-related condition, comprising administering to said subject a therapeutically effective amount of an isolated humanized protein binding to human Glycoprotein VI (hGPVI), wherein preferably said GPVI-related condition is a stroke, more preferably an acute ischemic stroke.

### Claim 32

A method for decreasing the risk of death in a subject affected with a GPVI-related condition, preferably for decreasing the risk of death within a time period of 20 days after the onset of the GPVI-related condition, preferably within a time period of 10 days after the onset of the GPVI-related condition, and even more preferably the risk of death within a time period of 5 days after the onset of the GPVI-related condition, the method comprising administering to said subject a therapeutically effective amount of an isolated humanized protein binding to human Glycoprotein VI (hGPVI), wherein preferably said GPVI-related condition is a stroke, more preferably an acute ischemic stroke.
